Clinical trials: Menopause
Pre-menopausal Breast Cancer, PI3K Pathway Inhibition
A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
Based on the evidence acquired in the post-menopausal setting with everolimus and on pre-clinical evidences supporting the investigation of PI3K inhibitors, such as alpelisib and buparlisib, in combination with endocrine therapy…
- Trial name
- B-YOND (NCT02058381)
- Testing
- alpelisib (BYL719), buparlisib (BKM120)
- Where
- 15 sites in Hong Kong, South Korea and 2 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
BRCA1 and/or BRCA2 Variant Carriers, Fertility
Study on Fertility Parameters in Women With Germline Variants in BRCA1 and BRCA2
Pathogenic variants (PVs) in the BRCA1 and BRCA2 genes are associated with an increased risk of developing breast and ovarian cancers.
- Conditions
- BRCA1 and/or BRCA2 Variant Carriers, Fertility, Reproductive Age, Menopause
- Trial name
- BFert (NCT06710015)
- Where
- Italy
- Volunteers
- 128 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Menopausal Women, Insomnia
Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms
The goal of this clinical trial is to learn how three current insomnia therapies (trazodone, daridorexant, cognitive behavioral therapy for insomnia) compare with each other in peri- and post-menopausal women.
- Trial name
- CELESTE (NCT07136415)
- Testing
- Cognitive behavioral therapy for insomnia (CBT-i), Trazodone, Daridorexant
- Where
- 5 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Brigham and Women's Hospital
Vulvodynia, Dyspareunia
Therapy to Prevent Sexual Pain in Breast Cancer Survivors
The purpose of this protocol is to determine whether pain with sexual intercourse can be reduced in menopausal, breast cancer survivors and to evaluate the effectiveness of a non-hormonal therapy (Lidocaine Liquid) vs.
- Conditions
- Vulvodynia, Dyspareunia, Breast Cancer, Menopause
- Trial name
- NCT01539317
- Testing
- Topical liquid lidocaine, Topical saline
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- OHSU Knight Cancer Institute
Body Weight Changes, Habits, Diet
Innovations Applied to the Pyrenean Beef Production to Enhance Consumer-identifiable Meat.
The DIETAPYR2 study is a randomized controlled crossover trial consisting of two experimental periods each lasting 8 weeks. Enrolled participants were randomly assigned to either a Pyrenean beef-based diet or a conventional…
- Conditions
- Body Weight Changes, Habits, Diet, Habit, Food, Life Change Events
- Trial name
- DIETAPYR2 (NCT04832217)
- Testing
- Pyrenees´ Beef diet
- Where
- Spain
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Universidad de Zaragoza
Endometriosis
Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women
This is a single-centre, open-label, within patient comparison study to assess the efficacy and safety of Decapeptyl SR when administered in combination with Livial for the treatment of women with chronic cyclical pelvic pain.
- Trial name
- NCT00735852
- Testing
- Decapeptyl SR 11.25mg
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Vasomotor Symptoms Associated With Menopause, Hot Flashes
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause
Researchers are looking for a better way to treat women who have hot flashes after they have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the…
- Trial name
- OASIS-3 (NCT05030584)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 86 sites in United States, Belgium and 7 more
- Volunteers
- 628 people
- Sponsor
- Bayer
Menopause
Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation
The purpose of this trial is to determine the equivalence of 3 new formulations of a Premarin®/medroxyprogesterone acetate (MPA) combination tablet to the currently marketed dosage form (Prempro® [TM]).
- Trial name
- NCT00630435
- Testing
- Premarin®/MPA formulation A, Premarin®/MPA formulation B, Premarin®/MPA formulation C
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Genitourinary Syndrome of Menopause
Vaginal CO2 Laser Therapy for Genitourinary Syndrome in Breast Cancer Survivors
This project will be based on three studies over a period on three years. The first study is a dose response study that includes 30 breast cancer survivors.
- Trial name
- NCT06007027
- Testing
- SmartXIDE2V2LR, Monalisa Touch, DEKA, Florence, Italy
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Age-associated Memory Impairment, Alteration of Cognitive Function
Hormones and Cognition in the Menopausal Transition
The purpose of this study is to determine if the menopausal transition is associated with subjective and objective cognitive declines that ameliorate in menopause.
- Trial name
- NCT01429103
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Vulvovaginal Atrophy, Menopause
RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity
Twelve month extension of a previous study of Multi-Polar RF and PEMF technologies for the treatment of vaginal laxity and for the treatment of the mons pubis and labia for improvement in skin laxity.
- Conditions
- Vulvovaginal Atrophy, Menopause, Menopause Surgical
- Trial name
- NCT04210583
- Testing
- Vulvovaginal Treatment
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Venus Concept
Perimenopausal Bone Loss
Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause
Study Objective: To determine whether Natto supplementation in women immediately after menopause might prevent severe bone loss Study population: Women 50 - 60 years, 1-5 years after menopause Study Design: Double-blind…
- Trial name
- NCT00290212
- Testing
- Natto capsules (food suppl.) cont. 360 microg. vit K2/day
- Where
- 2 sites in Norway
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- University Hospital of North Norway
Menopause
Sexual Functions and Marital Adjustment for Spouses in Menopause
Objective: This study was conducted as a cross-sectional descriptive study in order to determine the effect of menopause on the SFs and marital adjustment of the spouses.
- Trial name
- menopause (NCT05338645)
- Where
- Turkey (Türkiye)
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Hitit University
Menopausal Syndrome
HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness
Therefore, the aim of this study is to assess the therapeutic effect on overactive bladder symptoms, sexual function, heart rate variability, arterial stiffness, atherosclerosis, sleep, and depression between tibolone and…
- Trial name
- NCT05280028
- Testing
- Tibolone 2.5 mg, Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Far Eastern Memorial Hospital
Breast Cancer
Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer
RATIONALE: Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ATN-224 may stop the growth of breast cancer by blocking blood flow to the tumor.
- Trial name
- NCT00674557
- Testing
- SOD1 inhibitor ATN-224, exemestane, protein expression analysis
- Where
- United Kingdom
- Volunteers
- 111 people
- Sponsor
- Cancer Research UK
Menopause, Vaginal Atrophy
Vaginal Inflammation Markers in Postmenopausal Women With and Without Symptoms of Vaginal Inflammation
Many postmenopausal women suffer from vaginal symptoms such as dryness, itching, and painful intercourse. The underlying pathology is unknown.
- Trial name
- NCT01899612
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Metastatic Breast Cancer
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone
- Trial name
- NCT00696072
- Testing
- Dasatinib, Letrozole
- Where
- 27 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Menopause, Hypertension
Taekwondo Training and Postmenopausal Women With Stage-2 Hypertension
Aging is associated with hormonal imbalances and progressive decreases in arterial health and function. It is crucial to prevent or reduce the negative effects of aging on hormonal balance and the vasculature by implementing…
- Trial name
- NCT03544307
- Testing
- Taekwondo training
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kosin University
Osteoporosis, Postmenopausal, Osteopenia
High-Intensity Laser Therapy and Physiotherapy for Bone Health in Postmenopausal Women: A Randomized Trial
The goal of this clinical trial is to learn if adding high-intensity laser therapy (HILT) to a physiotherapy programme helps bone health in women after menopause who have low bone density (osteopenia or osteoporosis).
- Trial name
- NCT07734922
- Testing
- High-Intensity Laser Therapy, Standardised Physiotherapy Programme
- Where
- Romania
- Volunteers
- 40 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Major Depressive Disorder, Menopause
A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
HYPOTHESIS: Pregnenolone administration will be associated with greater reduction in depressive symptom severity than placebo in women with current mMDD.
- Conditions
- Major Depressive Disorder, Menopause, Perimenopause
- Trial name
- NCT03505905
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Texas Southwestern Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.